Dr Michael Lichtenberg today presented 36-Month Outcomes for the BioMimics 3D® Stent in Longer Lesions: A Subgroup Analysis of the MIMICS-3D EU Registry at VIVA 22

HORSHAM, UK – 01 Nov 2022 – Veryan Medical Ltd announces that Dr Michael Lichtenberg (Klinikum Hochsauerland, Arnsberg, Germany) today presented 36-Month Outcomes for the BioMimics 3D® Stent in Longer Lesions: A Subgroup Analysis of the MIMICS-3D EU Registry at VIVA 22 in the Late Breaking Clinical Trials session at VIVA 2022 in Las Vegas, US.

BioMimics 3D Vascular Stent System has FDA and CE Mark approval.
BioMimics 3D & Swirling Flow Stent are registered trademarks of Veryan Medical Limited.
Veryan Medical Limited is a member of the Otsuka Medical Devices group of companies.
CAUTION: Federal law restricts this device to sale by or on the order of a physician.

PAM 14 Version 3.0